Pivotal studies of orphan drugs approved for neurological diseases

Annals of Neurology

Volumn 66, Issue 2, 2009, Pages 184-190

  Mitsumoto, Jun ^a   Dorsey, E Ray ^b   Beck, Christopher A ^b   Kieburtz, Karl ^b   Griggs, Robert C ^b  

^a College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE BETA; APOMORPHINE; BETA1A INTERFERON; BOTULINUM TOXIN A; BOTULINUM TOXIN B; ESZOPICLONE; FOSPHENYTOIN SODIUM; GALSULFASE; GLATIRAMER; IDURONATE 2 SULFATASE; LAMOTRIGINE; LARONIDASE; MIGLUSTAT; MITOXANTRONE; MODAFINIL; OMEGA CONOTOXIN MVIIA; ORPHAN DRUG; OXYBATE SODIUM; PALIPERIDONE; PLACEBO; PREGABALIN; RAMELTEON; RASAGILINE; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RILUZOLE; ROTIGOTINE; TEMOZOLOMIDE; TOPIRAMATE; UNINDEXED DRUG; VARENICLINE;

ARTICLE; CONTROLLED STUDY; DRUG APPROVAL; DRUG DESIGN; DRUG LABELING; DRUG PACKAGING; FOOD AND DRUG ADMINISTRATION; METHODOLOGY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; UNITED STATES;

DRUG APPROVAL; HUMANS; NERVOUS SYSTEM DISEASES; ORPHAN DRUG PRODUCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 70149120097     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21676     Document Type: Article

References (42)

1. U.S. Food and Drug Administration. Cumulative list of all Orphan Designated Products that have received marketing approval. Available at: http://www.fda.gov/orphan/designat/allap.rtf. Accessed August 5, 2008.
2. US Food and Drug Administration. Orphan designations pursuant to Section 526 of the Federal Food and Cosmetic Act as amended by the Orphan Drug Act (P.L. 97-414). Available at: http://www.fda.gov/orphan/designat/list.xls. Accessed July 26, 2008.
3. US Food and Drug Administration. CDER Drug and Biologic Approval Reports: NME and new biologic approvals. Available at: http://www.fda.gov/Cder/rdmt/ default.htm. Accessed July 14, 2008.
4. Haffner ME. Adopting orphan drugs - two dozen years of treating rare diseases. N Engl J Med 2006;354:445-447.
5. Reaves ND. A model of effective health policy: the 1983 Orphan Drug Act. J Health Soc Policy 2003;17:61-71.
6. Rin-Laures L-H, Janofsky D. Recent developments concerning the Orphan Drug Act. Harv J Law Technol 1991;4:269-297.
7. Yin W. Market incentives and pharmaceutical innovation. J Health Econ 2008;27:1060-1077.
8. Drummond MF, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 2007;23:36-42. (Pubitemid 46648298)
9. Rohde DD. The Orphan Drug Act: an engine of innovation? At what cost? Food Drug Law J 2000;55:125-143.
10. US Food and Drug Administration. OOPD Program Overview. Rockville, MD, 2008. http://www.fda.gov/orphan/progovw.htm. Last accessed on May 22, 2008.
11. Adequate and well-controlled studies. Title 21 Code of Federal Regulations, pt. 314, sec. 126, 2007.
12. Buckley BM. Clinical trials of orphan medicines. Lancet 2008;371:2051-2055.
13. National Institute of Neurological Disorders and Stroke. Disorders Index. Available at: http://www.ninds.nih.gov/disorders/disorder-index.htm. Accessed March 28, 2008.
14. National Institute of Mental Health. Mental health topics. Available at: http://www.nimh.nih.gov/health/topics/index.shtml. Accessed March 28, 2008.
15. National Institute on Aging. About NIA. Available at: http://www.nia.nih.gov/AboutNIA/. Accessed July 20, 2008.
16. National Institute on Drug Abuse. Division of Clinical Neuroscience and Behavioral Research: Behavioral and Brain Development Branch. Available at: http://www.nida.nih.gov/about/organization/DCNBR/bbdb.html. Accessed March 28, 2008.
17. US Food and Drug Administration. New drug application approvals and receipts, including new molecular entities, 1938 to present. Available at: http://www.fda.gov/oc/history/NDAapprovals.html#data. Accessed July 22, 2008.
18. Applicability. Title 21 Code of Federal Regulations, pt. 312, sec. 2, 2003.
19. U.S. Food and Drug Administration. Drugs@FDA: FDA approved drug products. Available at: http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/. Accessed August 7, 2008.
20. Pfizer Inc. Cerebyx (fosphenytoin sodium injection), prescribing information. Available at: http://media.pfizer.com/files/products/uspi-cerebyx. pdf. Accessed June 23, 2008.
21. Sanofi-Aventis U.S. Rilutek (riluzole) tablets, prescribing information. Available at: http://products.sanofi-aventis.us/rilutek/rilutek.html. Accessed June 23, 2008.
22. Teva Pharmaceutical Industries Ltd. Copaxone (glatiramer acetate injection), prescribing information. Available at: http://www.copaxone.com/pdf/ PrescribingInformation.pdf. Accessed June 23, 2008.
23. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585-591.
24. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-1276.
25. Lacomblez L, Bensimon G, Leigh PN, et al. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology 1996;47:S242-S250. (Pubitemid 26422577)
26. Ramsay R, Philbrook B, Martinez O, et al. A double-blinded, randomized safety comparison of rapidly infused intravenous loading doses of fosphenytoin vs. phenytoin. Annual Meeting of the American Epilepsy Society, 1995. Baltimore, MD.
27. Teitelbaum D, Arnon R, Sela M, Abramsky O. [Clinical trial of copolymer 1 in multiple sclerosis]. Harefuah 1989;116:453-456.
28. Wilder BJ, Campbell K, Ramsay RE, et al. Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery. Arch Neurol 1996;53:764-768. (Pubitemid 26266922)
29. Allergen Inc. Botox (botulinum toxin type A), prescribing information. 2006. http://www.allergan.com/assets/pdf/botox-cosmetic-pi.pdf. Last accessed on July 22, 2008.
30. Chow SC, Chang M. Adaptive design methods in clinical trials - a review. Orphanet J Rare Dis 2008;3:11.
31. Coffey CS, Kairalla JA. Adaptive clinical trials: progress and challenges. Drugs R D 2008;9:229-242. (Pubitemid 351920122)
32. Temple R. FDA perspective on trials with interim efficacy evaluations. Stat Med 2006;25:3245-3249. (Pubitemid 44489391)
33. Gottlieb S. Speech. Available at: http://www.fda.gov/oc/speeches/2006/ trialdesign0710.html. Accessed July 14, 2008.
34. Cutler DM. The demise of the blockbuster? N Engl J Med 2007;356:1292-1293.
35. Lamb E. Top 200 prescription drugs of 2007. Plainsboro, NJ: Pharmacy Times, 2008.
36. Findings and purposes. Rare Diseases Act of 2002, Section 2, 2002.
37. Grabowski HG, Ridley DB, Schulman KA. Entry and competition in generic biologics. Managerial Economics 2007;28:439-451.
38. Lee K, Bacchetti P, Sim I. Publication of clinical trials supporting successful new drug applications: a literature analysis. PLoS Med 2008;5:e191.
39. Anello C. Integrated summaries of safety and integrated summaries of efficacy: is this meta-analysis? Available at: http://www.fda.gov/cder/Offices/ Biostatistics/Anello-193/index.htm. Accessed July 9, 2008.
40. Griggs R, Dunkle M, Batshaw M, et al. Clinical research for rare disease: opportunities, challenges and solutions. Mol Genet Metab 2009;96:20-26.
41. Maher PD, Haffner M. Orphan drug designation and pharmacogenomics: options and opportunities. BioDrugs 2006;20:71-79.
42. Samson K. Orphan economics: the downside of supplyside pharmacology. Ann Neurol 2008;64:A13-A16.